AstraZeneca Stomach Cancer Drug Doubles Median Survival in Later-Line Trial

AstraZeneca reported positive survival data from ESMO for bladder, lung, and gastric cancer treatments. Management noted growth opportunities in ADC and significant 2027 readouts. Data includes VOLGA, EGFR combinations, DeLLphi-305, and Sone-Ve results, according to the company.

AstraZeneca reported positive Phase III results for four oncology programs, including Imfinzi-based treatments and Tagrisso + Orpathys for lung cancer. The company reaffirmed its $80bn revenue target for 2030, citing a strong late-stage pipeline.

AstraZeneca's ADC sonesitatug vedotin showed improved survival in advanced gastric cancer patients with Claudin18.2 expression as low as 25%, per Phase III trial data presented at ESMO 2026.

Amgen and AstraZeneca reported a 58% reduction in death risk for a lung cancer treatment in trials. Merck and Moderna's cancer vaccine showed a 42% lower recurrence rate. Halloween candy sales fell 6.7% YoY. Dow dropped 600+ points as oil prices rose. Trump announced a $275M nursing initiative. Six Flags to add seatbelts after a fatality.

At ESMO 2026, Amgen and AstraZeneca presented data showing their combination therapy (Imdelltra + Imfinzi) reduced death risk by 58% in extensive-stage small-cell lung cancer. Roche's divarasib outperformed first-gen KRAS inhibitors in NSCLC, improving PFS and OS. MSD and Kelun-Biotech's sac-TMT with Keytruda showed PFS benefits in PD-L1-negative NSCLC. BioNTech's pumitamig showed potential in advanced NSCLC.

AstraZeneca's Phase III CLARITY-Gastric01 trial showed its experimental drug sonesitatug vedotin doubled median overall survival in later-line CLDN18.2 cancer patients, with 10 months vs. 5 months. The broader population saw a 42% reduction in death risk, but progression-free survival was not statistically significant. AstraZeneca estimates potential annual sales of $3B-$5B, per Bloomberg.